Used primarily in the treatment of multiple myeloma, a type of blood cancer. It works by inhibiting histone deacetylases (HDACs), which helps control the growth and survival of cancer cells. Often prescribed in combination with other drugs like bortezomib and dexamethasone for patients who have already undergone several lines of therapy. Its mechanism promotes cancer cell death by allowing increased expression of tumor-suppressing genes. Also being studied in clinical trials for other cancers, including lymphomas and solid tumors, due to its ability to alter gene expression and disrupt protein balance in malignant cells.